Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 61 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma PatientsCompletedNCT04473716Phase 1
• Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).Active, not recruitingNCT04472949Phase 2
• A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid TumorsStatus unknownNCT04472858Phase 1
• Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaStatus unknownNCT04472806Phase 2
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04471974Phase 2
• Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCCActive, not recruitingNCT04470024Phase 1
• KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic CarcinomaTerminatedNCT04469725Phase 2
• A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B PatientsCompletedNCT04465890Phase 2
• A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCCWithdrawnNCT04465734Phase 3
• Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorCompletedNCT04465643Phase 1
• A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced MelanomaActive, not recruitingNCT04464759Phase 1/2
• Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedNCT04463771Phase 2
• Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesCompletedNCT04463368Phase 1
• Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaActive, not recruitingNCT04462328Phase 1
• Thoracic RadiothErapy with Atezolizumab in Small Cell LUng CanceR Extensive DiseaseCompletedNCT04462276Phase 2
• A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.Status unknownNCT04460066Phase 1/2
• Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）Status unknownNCT04459611Phase 2
• Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT04459078Phase 2
• A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)Status unknownNCT04457869Phase 2
• The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Status unknownNCT04457830Phase 2
• Temozolomide, Cisplatin, and Nivolumab in People With Colorectal CancerCompletedNCT04457284Phase 2
• BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade TherapyActive, not recruitingNCT04454528Phase 1/2
• Hemopurifier Plus Pembrolizumab in Head and Neck CancerTerminatedNCT04453046Not applicable
• A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCompletedNCT04452214Phase 1
• Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04447612Phase 2
• A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPSStatus unknownNCT04447274Phase 2
• Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT04446663Phase 2
• Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingNCT04446351Phase 1
• INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyActive, not recruitingNCT04445844Phase 2
• EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsActive, not recruitingNCT04444921Phase 3
• Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaStatus unknownNCT04444193Not applicable
• A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaCompletedNCT04444167Phase 1/2
• A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT04444141Phase 1/2
• A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04443751Phase 1
• Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)Active, not recruitingNCT04443348Phase 2
• Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2
• Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ CarcinomaStatus unknownNCT04443036Not applicable
• A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesCompletedNCT04440943Phase 1
• Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell CarcinomaStatus unknownNCT04440917Phase 2
• Palbociclib and INCMGA00012 in People With Advanced LiposarcomaActive, not recruitingNCT04438824Phase 2
• Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal CancerStatus unknownNCT04437212Phase 2
• A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.Status unknownNCT04435652Phase 2/3
• Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT04435197Phase 2
• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerTerminatedNCT04432207Phase 1
• Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
• Cisplatin+Pembrolizumab+RT in Vulvar CancerActive, not recruitingNCT04430699Phase 2
• PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like CarcinomaStatus unknownNCT04430166Not applicable
• Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryTerminatedNCT04429321Phase 1
• Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell CancerActive, not recruitingNCT04428671Phase 1
• A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid TumorTerminatedNCT04427774Phase 1
• Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1
• Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal CancerStatus unknownNCT04426955Phase 3
• Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicable
• Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCStatus unknownNCT04425135Phase 2
• A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell LymphomaTerminatedNCT04425070Phase 1/2
• Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung CancerTerminatedNCT04422392Phase 2
• Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPCStatus unknownNCT04421469Phase 2
• Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC PatientsCompletedNCT04421352Phase 1
• Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaActive, not recruitingNCT04420975Phase 1
• A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）WithdrawnNCT04420130Not applicable
• Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent ChemoradiotherapyTerminatedNCT04418648Phase 2
• Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast CancerWithdrawnNCT04418219Phase 1/2
• Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer PatientsStatus unknownNCT04418154Phase 2
• Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2
• Pembrolizumab and Radiotherapy for Patients With NK/T Cell LymphomaActive, not recruitingNCT04417166Phase 2
• The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic CarcinomaStatus unknownNCT04415385Phase 2
• A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeActive, not recruitingNCT04414163Phase 2
• Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) InfectionStatus unknownNCT04413838Phase 2
• Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2
• Study on Sintilimab in Stage IV High Risk NeuroblastomaStatus unknownNCT04412408Early Phase 1
• The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal CancerStatus unknownNCT04411537Phase 2
• The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal CancerStatus unknownNCT04411524Phase 2
• First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCCompletedNCT04408118Phase 2
• Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT04405622Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)Status unknownNCT04405505Phase 3
• Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical CancerCompletedNCT04405349Phase 2
• Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer RecurrenceStatus unknownNCT04404491Phase 3
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).TerminatedNCT04404140Phase 1
• Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular CarcinomaCompletedNCT04401813Phase 1
• Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line ChemotherapyCompletedNCT04401774Phase 2
• Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant TumorsStatus unknownNCT04400851Phase 1
• Systemic Chemotherapy Plus PD-1 for Metastasis ICCWithdrawnNCT04398927Phase 2
• Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04398056Phase 2
• Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04397003Phase 2
• Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901Status unknownNCT04396457Phase 2
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological MalignanciesActive, not recruitingNCT04395079Phase 2
• Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell CarcinomaCompletedNCT04393506Phase 1
• Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular CarcinomaCompletedNCT04393220Phase 2
• Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyActive, not recruitingNCT04392505Phase 2
• Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal CancerStatus unknownNCT04390945Phase 2
• Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)Status unknownNCT04389177Phase 2
• Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon CancerStatus unknownNCT04389151Phase 2
• Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic VinorelbineStatus unknownNCT04389073Phase 2
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersActive, not recruitingNCT04388852Phase 1
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04387227Phase 2
• Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04385654Phase 2
• A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04385550Phase 3
• A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical CancerCompletedNCT04380805Phase 2

← Immune Checkpoint Inhibitors overview